MHLW Adds Ileus To Side Effects Of Nippon Boehringer Ingelheim’s Spiriva
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare added severe side effects of ileus to package inserts of Nippon Boehringer Ingelheim's Spiriva (tiotropium bromide), a drug to treat chronic obstructive pulmonary disease. Since launched in December 2004, four cases of ileus have been reported. According to the company, an estimated 180,000 patients in Japan are taking the drug every year. (Click here for more - Japanese language